Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v10-EN Version v4-EN
Language English English
Date Updated 2022-07-14 2022-04-21
Drug Identification Number 00392693 00392693
Brand name ATROPINE SULFATE INJECTION USP ATROPINE SULFATE INJECTION USP
Common or Proper name ATROPINE SO4 ATROPINE SO4
Company Name SANDOZ CANADA INCORPORATED SANDOZ CANADA INCORPORATED
Ingredients ATROPINE SULFATE ATROPINE SULFATE
Strength(s) .6MG .6MG
Dosage form(s) SOLUTION SOLUTION
Route of administration SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR
Packaging size 1ML 10LIAM 1ML 10LIAM
ATC code A03BA A03BA
ATC description BELLADONNAAND DERIVATIVES, PLAIN BELLADONNAAND DERIVATIVES, PLAIN
Reason for shortage Demand increase for the drug. Demand increase for the drug.
Anticipated start date 2022-04-20 2022-04-20
Actual start date
Estimated end date 2022-07-08 Unknown
Actual end date 2022-07-13
Shortage status Resolved Actual shortage
Tier 3 Status No No
Company comments Product is available on allocation at wholesalers, based on 100% of historical volumes. Product is available on allocation at wholesalers, based on 100% of historical volumes.
Health Canada comments